Last reviewed · How we verify
TELMINUVO Tab. (80/2.5mg)
Telminuvo is a selective inhibitor of the sodium-activated potassium channel, KCNN4.
Telminuvo is a selective inhibitor of the sodium-activated potassium channel, KCNN4. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TELMINUVO Tab. (80/2.5mg) |
|---|---|
| Also known as | TELMINUVO Tab. |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | KCNN4 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting KCNN4, Telminuvo reduces the activity of the channel, which is involved in the regulation of smooth muscle contraction and relaxation. This action is thought to contribute to the drug's therapeutic effects.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TELMINUVO Tab. (80/2.5mg) CI brief — competitive landscape report
- TELMINUVO Tab. (80/2.5mg) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI